Search the Newsreel

Harmony Biosciences Holdings (HRMY) Following A Fresh Bullish Narrative, Is The Valuation Case Compelling

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Event driven interest around Harmony Biosciences Holdings stock Fresh attention is turning to Harmony Biosciences Holdings (HRMY) after research firm Zacks assigned the …

Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings

HRMY Maintained by Mizuho -- Price Target Raised to $51.00

Mizuho has maintained an "Outperform" rating for Harmony Biosciences Holdings (HRMY) and increased its price target to $51.00, reflecting optimism for the biotechnology company. HRMY is currently valued at $34.76, indicating a 26.5% undervaluation according to GuruFocus's GF Value™ of $47.30, and holds a …

Mizuho Lifts Price Target on Harmony Biosciences Holdings to $51 From $50, Keeps Outperform Rating

Mizuho has increased its price target for Harmony Biosciences Holdings (HRMY) to $51 from $50, while reiterating an Outperform rating. This adjustment suggests a continued positive outlook on the company's stock performance.

HRMY or ACAD: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two stocks presents investors with the better value opportunity right now? Let's take a …

Should Value Investors Buy Harmony Biosciences (HRMY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Considering these trends, …

Harmony Biosciences Holdings Inc (HRMY) Valuation: PE, PB & Fair Value Analysis

Harmony Biosciences Holdings Inc (HRMY) has a current valuation score of 8.09, placing it 108th out of 155 in the Pharmaceuticals industry. The company's P/E ratio stands at 14.19, which is significantly below its recent high and above its recent low. Key valuation metrics …

Zacks.com featured highlights include Harmony Biosciences, Invesco, General Motors, Hewlett Packard and Quanex Building

This Zacks.com article highlights five undervalued price-to-book stocks: Harmony Biosciences, Invesco, General Motors, Hewlett Packard Enterprise, and Quanex Building Products. It explains the P/B ratio as a tool for identifying undervalued stocks, defining book value and its calculation, and discusses the importance of comparing …

Harmony Biosciences Holdings, I (HRMY) Stock Forecasts

Argus has lowered its target price for Harmony Biosciences Holdings Inc (HRMY) to $38.00. The company is a commercial-stage pharmaceutical firm specializing in therapies for rare neurological diseases. The current price of HRMY stock is $35.86.

HRMY|Harmony Biosciences Holdings Inc|Price:35.138|Chg%:-0.722

Harmony Biosciences Holdings Inc (HRMY) shows strong fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. The company's revenue has grown significantly, and it boasts high profit growth and institutional confidence. Analysts have rated the stock as "Buy" with an …

BlackRock (HRMY holder) discloses 6.53M Harmony Biosciences shares in 13G/A

BlackRock, Inc. has filed an amended Schedule 13G/A revealing a beneficial ownership of 6,525,663 shares of Harmony Biosciences Holdings, Inc. common stock, which represents an 11.3% stake in the company. BlackRock exercises sole voting power over 6,445,523 shares and sole dispositive power over all …

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences Holdings, Inc. (HRMY) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2026, with Wall Street anticipating $0.97 EPS and $252.54 million in revenue. The company holds a Zacks Rank of #1 (Strong Buy) and …

Harmony Biosciences Holdings Inc (HRMY) Income Statement

This article provides the quarterly and annual income statements for Harmony Biosciences Holdings Inc (HRMY), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes key financial metrics and answers frequently asked questions about analyzing …

Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?

Neurocrine Biosciences NBIX is scheduled to report second-quarter 2026 results on July 30, after market close. We expect investors to focus on the sales performance of NBIX's marketed products and other pipeline updates when the company reports quarterly results. The Zacks Consensus Estimate for …

Harmony Biosciences Holdings Inc

This article provides key financial data for Harmony Biosciences Holdings Inc (HRMY), including its market capitalization of $2.08 billion and a P/E TTM of 14.25. It shows the company's revenue breakdown by region, with $868.45 million from the United States, but notes that detailed …

Did CFO Exit and Reaffirmed 2026 Guidance Just Shift Harmony Biosciences' (HRMY) Investment Narrative?

Harmony Biosciences (HRMY) recently announced the departure of its CFO, Glenn Reicin, and the appointment of an interim CFO. Despite this leadership change, the company reaffirmed its full-year 2026 net product revenue guidance of US$1.00 billion to US$1.04 billion, indicating continued confidence in its …

HRMY|Harmony Biosciences Holdings Inc|Price:35.780|Chg%:+0.920

Harmony Biosciences Holdings Inc. (HRMY) shows strong fundamentals with high revenue and profit growth, despite its stock trading sideways recently. The company, focused on rare neurological diseases, has a "Buy" rating from analysts with a target price of $44.91, and its valuation is considered …

ETFs Investing in Harmony Biosciences Holdings, Inc. Stocks

This article lists various ETFs that currently hold Harmony Biosciences Holdings, Inc. (HRMY) stocks, providing detailed information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year total return. The ETFs mainly focus on small-cap …

Harmony Biosciences (HRMY) Says Goodbye To Its CFO And Names An Interim Finance Chief

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Harmony Biosciences Holdings (NasdaqGM:HRMY) announced that Chief Financial Officer Glenn Reicin has resigned. The company named Stephen Mollichella as interim Principal Financial Officer, effective …

Harmony Biosciences (HRMY) officer details stock and option holdings

Stephen M. Mollichella, "INT PRINCIAL FINANCIAL OFFICER" at Harmony Biosciences (HRMY), has reported his initial beneficial ownership on a Form 3 filing. The filing details his holdings in stock options, restricted stock units, and directly owned common stock. These holdings include various vesting schedules …

Harmony Biosciences interim principal financial officer Stephen Mollichella files initial beneficial ownership statement

Stephen Mollichella, interim principal financial officer of Harmony Biosciences, has filed his initial beneficial ownership statement (Form 3). The filing indicates he holds 2,506 common shares, stock options for 48,472 shares with exercise prices between $30.69 and $38.01, and 12,013 restricted stock units. This …

Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?

Harmony Biosciences (HRMY) shares surged 10% after the company reported stronger-than-expected preliminary second-quarter 2026 results, with Wakix net product revenue reaching a record $261 million. The company reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion, driven by robust demand and …

Harmony Biosciences Holdings Jumps 9.6% Amid Sector-Wide Rally

Harmony Biosciences (HRMY) shares surged 9.6% following a broad rally across the biotechnology sector. The increase brought the company's shares to $36.73, with trading volume reaching 1.2M shares. This sector-wide momentum, rather than company-specific news, appears to be the primary driver for the gains, …

Harmony Biosciences to report Q2 2026 results on August 4

Harmony Biosciences Holdings, Inc. will announce its Q2 2026 financial results on Tuesday, August 4, 2026, before market open. A conference call and webcast will be held at 8:30 a.m. ET to discuss these results, with investors able to participate via specific dial-in numbers …

Harmony Biosciences will host a live Q2 results webcast on Aug. 4

Harmony Biosciences (Nasdaq: HRMY) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, before the U.S. market opens. The company will also host a conference call and live webcast for investors and analysts at 8:30 a.m. ET on …

H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)

H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Harmony Biosciences Holdings Inc. (HRMY). The analyst also maintained a price target of $55.00 for the company's stock. This article is behind a paywall and requires a premium subscription to read the full …

H.C. Wainwright reiterates Harmony Biosciences stock rating on demand beat

H.C. Wainwright reiterated a Buy rating and a $55 price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) after the company announced stronger-than-expected second-quarter revenue. The beat was attributed to increased demand, leading H.C. Wainwright to modestly raise its full-year 2026 net product revenue estimate …

Harmony Bio drops after CFO exit

Harmony Bio's stock fell sharply following the unexpected departure of its Chief Financial Officer. The company has not yet named a successor, leading to investor uncertainty. This executive change raises questions about the company's financial stability and future strategic direction.

HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition

Harmony Biosciences (HRMY) announced strong preliminary Q2 2026 net product revenues of $261 million for its drug Wakix, a 30% year-over-year increase, and reiterated its full-year guidance of $1.0 billion to $1.04 billion. Concurrently, the company announced the departure of CFO Glenn Reicin, with …

Harmony Biosciences reaffirms 2026 net revenue outlook of $1 billion-$1.04 billion

Harmony Biosciences has reaffirmed its net revenue guidance for WAKIX in 2026, projecting between $1 billion and $1.04 billion. This outlook is supported by strong preliminary second-quarter WAKIX net revenue of approximately $261 million, marking a 30% year-over-year increase and a 21% rise from …

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Harmony Biosciences announced record preliminary, unaudited net product revenue of approximately $261 million for WAKIX® in Q2 2026, a 30% year-over-year increase, and reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion. The company also announced the departure of …

Harmony Biosciences reports record Q2 WAKIX sales of $261M

Harmony Biosciences Holdings, Inc. announced record preliminary, unaudited second-quarter 2026 net product revenue of $261 million for WAKIX, representing a 30% year-over-year increase. The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, driven by strong demand and …

Harmony Biosciences Announces CFO Transition as Glenn Reicin Steps Down

Harmony Biosciences announced that CFO Glenn Reicin has stepped down, effective July 16, 2026, to pursue other opportunities. Stephen Mollichella, SVP and controller, has been appointed interim principal financial officer. The company also reported record preliminary second-quarter revenue of approximately $261 million for WAKIX® …

GUIDANCE: (HRMY) Harmony Biosciences Expects Q2 Wakix Net Product Revenue About $261M

Harmony Biosciences (HRMY) announced it expects its second-quarter Wakix net product revenue to be approximately $261 million. This projection indicates continued strong performance for their primary product. The financial guidance provides a positive outlook for the company's Q2 results.

Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement

Harmony Biosciences reported preliminary second-quarter net product revenue for WAKIX of approximately $261 million, a new record, and reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion. Concurrently, the company announced that CFO Glenn Reicin stepped down, with Stephen Mollichella appointed …

Harmony Bio stock drops after CFO exit (HRMY:NASDAQ)

Harmony Biosciences (HRMY) stock declined following the resignation of its Chief Financial Officer, Glenn Reicin, who left to pursue other career opportunities. Stephen Mollichella, the SVP and Controller, has been appointed as the Interim Principal Financial Officer to oversee financial operations for the rare …